FOXM1

(redirected from INS-1)

FOXM1

A gene on chromosome 12p13 that encodes a member of the forkhead family of transcription factors, which is thought to play a role in controlling cell proliferation.
References in periodicals archive ?
Insmed Incorporated (Nasdaq: INSM) today announced that three abstracts will be presented at The Endocrine Society's 84th Annual Meeting, ENDO 2002, detailing recent research with two of its lead compounds, SomatoKine(R) and INS-1.
Sinai School of Medicine, will give poster presentations revealing their research involving SomatoKine and INS-1 respectively.
Insmed Incorporated (Nasdaq: INSM) today announced that results of Phase II clinical trials of INS-1 and SomatoKine(R) in patients with type 2 diabetes will be presented at three poster sessions at the American Diabetes Association's 62nd Annual Scientific Sessions.
The Company will present data from the most recent Phase II clinical trial of SomatoKine(R) for the treatment of type 2 diabetes and the Company will present two additional posters that will detail the results of additional analyses from previously reported clinical trial data with INS-1 in type 2 diabetes.
The collaborative study involves collecting blood samples and phenotypic data from subjects that have been diagnosed with PCOS who are currently enrolled in clinical trials designed to evaluate the effects of Insmed's product candidate INS-1 and additional control subjects who do not have PCOS.
The Company is developing INS-1 for the treatment of type 2 diabetes and polycystic ovary syndrome, a significant women's health disorder.
Insmed Incorporated (Nasdaq: INSM) will conduct two poster sessions at the American Diabetes Association's 61st Annual Scientific Sessions, detailing the safety and efficacy of each of its two lead compounds, INS-1 and SomatoKine(R).
Despite strong demand for existing agents, most have less than optimal side effect profiles, creating a significant market opportunity for both INS-1 and SomatoKine.
The two abstracts presented to the ADA will detail the efficacy of both of the company's lead compounds, INS-1 and SomatoKine.
INS-1 is an orally-active insulin sensitizer, which restores tissue sensitivity to insulin.
Insmed Incorporated (Nasdaq: INSM) today announced positive results following a full analysis of its recently completed clinical trial of Type 2 diabetes patients treated with INS-1 in combination with sulfonylureas.
The net proceeds from the offering will be used to fund the continued developed of INS-1 and SomatoKine(R), as well as for working capital and general corporate purposes.